Patents by Inventor Indranil Nandi

Indranil Nandi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220273670
    Abstract: The present invention discloses an extended release oral liquid pharmaceutical composition comprising eslicarbazepine or its pharmaceutically acceptable esters, salts, solvates, polymorphs, enantiomers or mixtures thereof in a pharmaceutically acceptable carrier. The extended release liquid compositions are in the form of ready-to-use liquid compositions or reconstituted liquid compositions. It also relates to processes for the preparation of said extended release liquid compositions. The prior art discloses immediate release oral liquid dosage form. The prepared novel test formulations exhibited desired pharmaceutical technical attributes.
    Type: Application
    Filed: May 17, 2022
    Publication date: September 1, 2022
    Applicant: Jubilant Generics Limited
    Inventors: Dinesh Kumar, Indranil Nandi, Rakesh K. Singh
  • Publication number: 20220265552
    Abstract: The present invention relates to oral ready to use liquid pharmaceutical compositions of eslicarbazepine. It also relates to the processes for the preparation of said liquid compositions. The present invention provides liquid compositions of eslicarbazepine with desired technical attributes such as release profile, viscosity, pH, stability, and acceptable organoleptic properties. The prepared compositions are useful in patients having difficulties in swallowing tablets and provide the physician with providing a more convenient and less cumbersome posology. The suspension compositions as per present invention are useful for the treatment of seizures, partial-onset seizures, epilepsy, neuropathic pain, migraine, fibromyalgia, trigeminal neuralgia, bipolar disorders, attention disorders, anxiety disorders, affective disorders, schizoaffective disorders, sensorimotor disorders, and vestibular disorders.
    Type: Application
    Filed: May 2, 2022
    Publication date: August 25, 2022
    Applicant: Jubilant Generics Limited
    Inventors: Indranil Nandi, Dinesh Kumar, Rakesh Singh, TUSHARMOULI MUKHERJEE
  • Publication number: 20220202698
    Abstract: Provided herein are the extended release pharmaceutical composition suitable for once or twice daily dosing comprising riociguat and at least one or more pharmaceutically acceptable excipients. The present invention also relates to method for preparing extended release composition and method of using these dosage forms for the treatment of pulmonary hypertension and related diseases. The present invention provides extended release composition of riociguat which are expected to exhibit desired technical attributes such as assay, stability and release profile suitable for once or twice daily administration.
    Type: Application
    Filed: December 27, 2021
    Publication date: June 30, 2022
    Applicant: Jubilant Pharma Holdings Inc.
    Inventors: Indranil Nandi, Tusharmouli Mukherjee, Dinesh Kumar, Rakesh Kumar Singh
  • Patent number: 11331324
    Abstract: The present invention discloses an extended release oral liquid pharmaceutical composition comprising eslicarbazepine or its pharmaceutically acceptable esters, salts, solvates, polymorphs, enantiomers or mixtures thereof in a pharmaceutically acceptable carrier. The extended release liquid compositions are in the form of ready-to-use liquid compositions or reconstituted liquid compositions. It also relates to processes for the preparation of said extended release liquid compositions. The prior art discloses immediate release oral liquid dosage form. The prepared novel test formulations exhibited desired pharmaceutical technical attributes.
    Type: Grant
    Filed: March 24, 2020
    Date of Patent: May 17, 2022
    Inventors: Dinesh Kumar, Saurabh Srivastava, Indranil Nandi, Rakesh K. Singh, Amit Jha, Kamal S. Mehta
  • Patent number: 11327065
    Abstract: The present invention relates to a process for the preparation of angiotensin receptor blockers or its pharmaceutically acceptable salts thereof containing less than 10 ppm of the azido impurities.
    Type: Grant
    Filed: August 27, 2021
    Date of Patent: May 10, 2022
    Inventors: Saji Thomas, Rajendra Shekhawat, M. Umamaheshwar Prasad, Bidyut Biswas, Rohit Chakravarthy, Chetan Balubhai Patel, Anilkumar Haribhat Lingabhat, Mohan Chikmagalur Sadashivappa, Indranil Nandi
  • Patent number: 11318145
    Abstract: The present invention relates to oral ready to use liquid pharmaceutical compositions of eslicarbazepine. It also relates to the processes for the preparation of said liquid compositions. The present invention provides liquid compositions of eslicarbazepine with desired technical attributes such as release profile, viscosity, pH, stability, and acceptable organoleptic properties. The prepared compositions are useful in patients having difficulties in swallowing tablets and provide the physician with providing a more convenient and less cumbersome posology.
    Type: Grant
    Filed: May 21, 2021
    Date of Patent: May 3, 2022
    Inventors: Indranil Nandi, Tusharmouli Mukherjee, Dinesh Kumar, Rakesh K. Singh, Saurabh Srivastava
  • Patent number: 11311518
    Abstract: Disclosed are the injection compositions of ?3 adrenoreceptor agonists such as mirabegron or their pharmaceutically acceptable salts or solvates or esters thereof. The present invention also relates to methods for preparing injection compositions and methods of using these dosage forms for the treatment of obesity, other related metabolic diseases, and reduction/removal of fat. The injection compositions as per the present invention have advantages of simple preparation, simple and convenient application, easy absorption, and better effect of treating. The compositions can also be used in cases where oral administration of the drug is not possible due to underlying conditions or concerns around inadequate oral absorption. The injection compositions as per the present invention have desirable pharmaceutical technical attributes.
    Type: Grant
    Filed: August 6, 2021
    Date of Patent: April 26, 2022
    Assignee: Jubilant Pharma Holdings Inc.
    Inventors: Indranil Nandi, Tusharmouli Mukherjee, Nagabasayya R Chikkamath
  • Publication number: 20220062288
    Abstract: The present invention relates to methods and compositions of vibegron or its pharmaceutically acceptable salts, esters, solvates, polymorphs, enantiomers, or mixtures thereof for reducing body fat. The present invention further provides a method of treating localized fat, double chin disorder, benign symmetric lipomatosis, adiposis dolorosa, lipedema, and familial partial lipodystrophy in a subject by administration of the parenteral pharmaceutical compositions of vibegron. It also relates to a process for the preparation of such compositions.
    Type: Application
    Filed: September 1, 2021
    Publication date: March 3, 2022
    Applicant: Jubilant Pharma Holdings Inc.
    Inventor: Indranil Nandi
  • Publication number: 20220062213
    Abstract: Provided herein are compositions and methods useful in the non-surgical removal of fat deposits in patients in need thereof using ?3-adrenoreceptor agonists. The invention further provides a method of treating double chin disorder, benign symmetric lipomatosis, adiposis dolorosa, lipedema, and familial partial lipodystrophy in patients in need thereof by administration of solabegron or its pharmaceutically acceptable salts, esters, solvates, polymorphs, enantiomers, or mixtures thereof. The treatment method as per the present invention comprises treatment with solabegron or its pharmaceutically acceptable salts, esters, solvates, polymorphs, enantiomers, or mixtures thereof suitable for injection administration. The compositions and treatment method as per the present invention have advantages of simple preparation, simple and convenient application, easy absorption, and better effect of treating without requiring any surgical procedure.
    Type: Application
    Filed: September 1, 2021
    Publication date: March 3, 2022
    Applicant: Jubilant Pharma Holdings Inc.
    Inventor: Indranil Nandi
  • Publication number: 20220040196
    Abstract: The present invention relates to a stable pharmaceutical composition comprising a combination of chlordiazepoxide hydrochloride and clidinium bromide and one or more pharmaceutically acceptable excipients, wherein the composition is in the form of solid oral dosage forms like capsule and sachet. The technical challenges like undesirable impurities in dosage form were successfully controlled by using: a) low moisture excipients; and b) formulation development under controlled temperature and controlled humidity conditions. The formulations as per the present invention are stable and exhibit desired pharmaceutical technical attributes like assay and dissolution. The prepared formulations are useful for the treatment of gastrointestinal disorders and various other therapeutic indications as described herein.
    Type: Application
    Filed: August 6, 2021
    Publication date: February 10, 2022
    Applicant: Jubilant Pharma Holdings Inc.
    Inventors: Indranil Nandi, Anil Jain, Saurabh Srivastava, Munish Dhiman
  • Publication number: 20220000843
    Abstract: Provided herein are the long-acting injection compositions of ?3 adrenoreceptor agonists like mirabegron or their pharmaceutically acceptable salts or esters thereof. The present invention also relates to methods for preparing long-acting injection compositions and methods of using these dosage forms for the treatment of obesity, metabolic diseases, and other diseases as described herein. The long-acting injection compositions as per the present invention have desirable pharmaceutical technical attributes.
    Type: Application
    Filed: June 30, 2021
    Publication date: January 6, 2022
    Applicant: Jubilant Pharma Holdings Inc.
    Inventors: Indranil Nandi, Tusharmouli Mukherjee
  • Publication number: 20210369619
    Abstract: The present invention relates to the transmucosal dosage forms like sublingual pharmaceutical compositions comprising antiviral molecules like favipiravir, remdesivir, baloxavir marboxil, molnupiravir, besifovir, raltegravir, GS-441524, ravidasvir, and other antiviral drugs. The present invention also relates to methods for preparing these transmucosal pharmaceutical compositions. Compositions prepared as per the present invention are able to increase bioavailability by avoiding first-pass metabolism. The compositions prepared as per the present invention exhibit desired pharmaceutical technical attributes such as pH, assay, related substance, disintegration, and dissolution. The compositions prepared as per the present invention are useful in the treatment of viral infections including coronavirus infection (COVID-19).
    Type: Application
    Filed: May 25, 2021
    Publication date: December 2, 2021
    Applicant: Jubilant Generics Limited
    Inventors: Indranil Nandi, Tusharmouli Mukherjee, Dinesh Kumar, Anil Jain, Pankaj Soni, Gaurav Navinbhai Mistry, Nilesh Jaiswal
  • Publication number: 20210361785
    Abstract: The present invention relates to stable pharmaceutical compositions of sulfur colloid, which advantageously provide a high radiochemical purity to 99mTc-pertechnetate without causing the gel formation. The compositions include pre-lyophilized and lyophilized compositions of sulfur colloid. It also relates to a non-radioactive kit which upon reconstitution with 99mTc-pertechnetate solution gives stabilized 99mmTc-Sulfur colloid radiopharmaceutical composition. Further, the process for preparation of said compositions and their use for diagnostic purposes are also disclosed.
    Type: Application
    Filed: October 7, 2019
    Publication date: November 25, 2021
    Applicant: Jubilant Generics Limited
    Inventors: Sanjeev Kumar, Rajesh Kumar, Brijesh Kumar Shukla, Rajendra Singh Shekhawat, Sujay Biswas, Dharam Vir, Nirmal Kumar, Indranil Nandi
  • Publication number: 20210353546
    Abstract: The present invention relates to a pharmaceutical composition comprising a combination of mirabegron and solifenacin or their pharmaceutically acceptable salts, wherein the composition comprises mini-tablets, multiparticulates, inlay tablets, or bilayer tablets. The prior art discloses restrictive formulation techniques and suggests complexity for preparing the combination in a single formulation to achieve the desired technical attributes. The test formulations are stable and exhibit desired pharmaceutical technical attributes. The invention also relates to the use of the pharmaceutical composition of the present invention in the treatment of various diseases like overactive bladder and other related therapeutic indications.
    Type: Application
    Filed: May 11, 2021
    Publication date: November 18, 2021
    Applicant: Jubilant Pharma Holdings Inc.
    Inventors: Indranil Nandi, Tusharmouli Mukherjee
  • Publication number: 20210322345
    Abstract: The invention provides oral liquid midodrine formulation and uses thereof.
    Type: Application
    Filed: March 15, 2021
    Publication date: October 21, 2021
    Inventors: Indranil Nandi, Ketan Hippalgaonkar, Sunil Vandse, Rish J. Vachhani
  • Publication number: 20210275546
    Abstract: The present invention relates to high drug load solid oral pharmaceutical compositions comprising dexamethasone or its pharmaceutically acceptable salts or solvates thereof. The present invention also relates to a process for preparing high drug load solid oral pharmaceutical compositions comprising dexamethasone or its pharmaceutically acceptable salts or solvates thereof. The preferred drug load in the compositions of the present invention is from about 26% to 50% by weight based on the total weight of the composition. The prepared compositions of dexamethasone as per the present invention exhibit desirable technical attributes.
    Type: Application
    Filed: May 13, 2021
    Publication date: September 9, 2021
    Applicant: Jubilant Pharma Holdings Inc.
    Inventor: Indranil Nandi
  • Publication number: 20210275539
    Abstract: The present invention relates to oral ready to use liquid pharmaceutical compositions of eslicarbazepine. It also relates to the processes for the preparation of said liquid compositions. The present invention provides liquid compositions of eslicarbazepine with desired technical attributes such as release profile, viscosity, pH, stability, and acceptable organoleptic properties. The prepared compositions are useful in patients having difficulties in swallowing tablets and provide the physician with providing a more convenient and less cumbersome posology.
    Type: Application
    Filed: May 21, 2021
    Publication date: September 9, 2021
    Applicant: Jubilant Generics Limited
    Inventors: Indranil Nandi, TUSHARMOULI MUKHERJEE, Dinesh Kumar, Rakesh K. Singh, Saurabh Srivastava
  • Publication number: 20210236629
    Abstract: The present invention relates to self-emulsifying pharmaceutical compositions in the field of allergen(s) and/or allergenic extract(s). Further within the scope of the invention is self-emulsifying oral pharmaceutical compositions and kits for compounding pharmaceuticals compositions that include at least one allergen as an active agent and one or more pharmaceutically acceptable excipients. The present invention also relates to processes for preparing such compositions. These pharmaceutical compositions are useful in the treatment of various types of allergies such as drug allergy, food allergy, insect allergy, latex allergy, mold allergy, pet allergy, and pollen allergy.
    Type: Application
    Filed: February 3, 2021
    Publication date: August 5, 2021
    Applicant: Jubilant Pharma Holdings Inc.
    Inventor: Indranil Nandi
  • Publication number: 20210236628
    Abstract: The present invention relates to self-emulsifying pharmaceutical compositions in the field of allergen(s) and/or allergenic extract(s). Further within the scope of the invention is self-emulsifying solid oral pharmaceutical compositions comprising at least one allergen as an active agent and one or more pharmaceutically acceptable excipients. The present invention also relates to processes for preparing such compositions. These pharmaceutical compositions are useful in the treatment of various types of allergies such as drug allergy, food allergy, insect allergy, latex allergy, mold allergy, pet allergy, and pollen allergy.
    Type: Application
    Filed: February 3, 2021
    Publication date: August 5, 2021
    Applicant: Jubilant Generics Limited
    Inventor: Indranil Nandi
  • Patent number: 11020349
    Abstract: Disclosed herein are the sublingual pharmaceutical compositions comprising remdesivir or its pharmaceutically acceptable salts or solvates thereof. The present invention also relates to a process for preparing sublingual pharmaceutical compositions comprising remdesivir or its pharmaceutically acceptable salts or solvates thereof. Compositions of remdesivir prepared as per present invention are able to increase bioavailability by avoiding first-pass metabolism. The compositions of remdesivir prepared as per present invention are useful in the treatment of viral infections including coronavirus infection (COVID-19). The compositions of remdesivir prepared as per present invention exhibit desired pharmaceutical technical attributes such as pH, assay, related substance, disintegration and dissolution.
    Type: Grant
    Filed: July 14, 2020
    Date of Patent: June 1, 2021
    Inventors: Indranil Nandi, Anil Jain, Ganesh Vinayak Gat